Acceptability and Feasibility of an Educational Intervention to Improve Researcher-Participant Interactions in a Neonatal Intensive Care Unit Clinical Trial: Research Team Feedback on the BRIEF Intervention.

Am J PerinatolFeb 20, 2026 (epub)
Clinical ResearchPediatricsOpen access

Stephanie A Kraft, Devan M Duenas, Andrea Kelsh et al.

✦ AI-curated · Sources linked

In 30 seconds

This single-site pilot study evaluated the feasibility and acceptability of Better Research Interactions for Every Family (BRIEF), a multipart educational intervention for improving research-team conversations with families about clinical trial enrollment in a neonatal intensive care unit. All nine research team members completed the online module, group training, surveys, self-assessments, and interviews. Team members reported greater satisfaction with BRIEF than with previous recruitment training. After training, self-assessments showed significant increases in reported partnership with bedside nursing (p = 0.02) and confirmation of family names (p = 0.05). Interviews also identified a need for more support with challenging conversations.

Key findings

  • All nine research team members completed every component of the BRIEF intervention.
  • Self-assessed partnership with bedside nursing increased after training (p = 0.02).
  • Self-assessed confirmation of family names increased after training (p = 0.05).
  • Team members reported high satisfaction with BRIEF, while identifying support for challenging conversations as an area for improvement.

Why it matters

Recruitment conversations can shape families’ understanding and decisions about research participation. This pilot suggests that structured communication training can be implemented and is acceptable to a neonatal research team, while also highlighting that training may need to address difficult conversations. The findings offer preliminary evidence about implementation and perceived skill changes, rather than demonstrating effects on family decision-making or enrollment.

What to keep in mind

This was a single-site pilot involving nine research team members. Skill changes were based on self-assessments, and the abstract does not report outcomes for families or trial enrollment.

Source

Published in Am J Perinatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.